Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Harvard Business School
Colorcon
AstraZeneca
US Army
Daiichi Sankyo

Generated: May 19, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,362,178

« Back to Dashboard

Summary for Patent: 6,362,178
Title: 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
Abstract:The 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position are prepared from the corresponding 2-phenyl-imidazotriazinones by chlorosulphonation and subsequent reaction with the amines. The compounds inhibit cGMP-metabolizing phosphodiesterases and are suitable for use as active compounds in pharmaceuticals, for the treatment of cardiovascular and cerebrovascular disorders and/or disorders of the urogenital system, in particular for the treatment of erectile dysfunction.
Inventor(s): Niewohner; Ulrich (Wermelskirchen, DE), Es-Sayed; Mazen (Langenfeld, DE), Haning; Helmut (Wuppertal, DE), Schenke; Thomas (Gladbach, DE), Schlemmer; Karl-Heinz (Wuppertal, DE), Keldenich; Jorg (Wuppertal, DE), Bischoff; Erwin (Wuppertal, DE), Perzborn; Elisabeth (Wuppertal, DE), Dembowsky; Klaus (Boston, MA), Serno; Peter (Gladbach, DE), Nowakowski; Marc (Wuppertal, DE)
Assignee: Bayer Aktiengesellschaft (Leverkusen, DE)
Application Number:09/554,162
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,362,178
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 6,362,178
Patent Claim Types:
see list of patent claims
Compound; Use;

Drugs Protected by US Patent 6,362,178

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,362,178

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany197 50 085Nov 12, 1997
Germany198 12 462Mar 23, 1998
Germany198 40 289Sep 04, 1998
PCT Information
PCT FiledOctober 31, 1998PCT Application Number:PCT/EP98/06910
PCT Publication Date:May 20, 1999PCT Publication Number: WO99/24433

International Family Members for US Patent 6,362,178

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 013759 ➤ Try a Free Trial
Argentina 035972 ➤ Try a Free Trial
Austria 213246 ➤ Try a Free Trial
Australia 1558799 ➤ Try a Free Trial
Australia 738675 ➤ Try a Free Trial
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Julphar
Accenture
Healthtrust
Deloitte
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.